AMDL, INC. Announces the Initiation of Commercial Sales
TUSTIN, Calif., Aug. 1 /PRNewswire/ -- AMDL, Inc. (OTCBB:AMDD) today announced that it has received an initial order for its
DR-70 cancer diagnostic kit from China under the recently renegotiated distribution agreement. Sales have also begun in Brazil,
Malaysia and Poland. The orders represent modest income at this time, but mark an important milestone for AMDL in that it is the true
beginning of commercial sales for the company. We are anticipating a very nice ramping up as the company moves forward both with
other products and distributors around the world.
AMDL, Inc. is a biomedical company applying immunochemical technology to develop novel diagnostic tests for use in the diagnosis
of cancer and other diseases.
Note: Certain statements in this announcement that relate to AMDL, Inc.'s plans, objectives or future performance may be deemed
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on
management's current expectations. Actual strategies and results in future periods may differ materially from those currently expected
because of various risks and uncertainties. Additional discussion of factors affecting AMDL, Inc.'s business and prospects is contained
in its periodic filings with the Securities and Exchange Commission. |
